SPARC enters pact with University of California, San Francisco, Tiller Therapeutics for Pre-clinical Oncology asset
Mumbai: Sun Pharma Advanced Research Company Ltd. (SPARC) has announced the signing of a binding Letter of Intent (LOI) with the University of California, San Francisco (UCSF) through the office of OTMA, and Tiller Therapeutics Inc. to license SPARC’s rights in the joint intellectual property (IP) held between SPARC and UCSF for pre-clinical oncology asset along with associated IP.
The LOI outlines the key terms of license and rights for development and commercialization by Tiller.
Under the terms of the LOI, SPARC will receive 55% equity stake in Tiller upon execution of LOI. The equity will vest in two tranches; 45% equity will vest upon execution of license agreement and the remaining 10% equity will vest at the earlier of achievement of certain milestones by Tiller or within 6 months of execution of license agreement. Other terms of the license will be outlined in the license agreement.
Anil Raghavan CEO of SPARC commented, "We are excited about the opportunity to partner with Tiller to advance potential treatment of solid tumors affecting millions each year, with no current cure.”
Read also: SPARC announces retirement of Dr Chitturi Trinadha Rao - Senior Vice President, Drug Discovery
SPARC is a clinical stage bio-pharmaceutical company. SPARC was formed in 2007 through a demerger from SUN PHARMA.
